Orthocell Reports On-Track Status Of Ortho-ATI’s Shoulder Tendon Clinical Trial

Orthocell Reports On-Track Status Of Ortho-ATI’s Shoulder Tendon Clinical Trial

Orthocell Limited (ASX: OCC) is in the business of developing regenerative medicines. The company’s key focus is developing medicines for regenerating mobility for patients by targeting the repair of a variety of soft tissue injuries.

The company’s product portfolio includes CelGro, a collagen medical device which uses a variety of reconstructive, orthopaedic and surgical applications to help the tissue’s healing and repair. It recently received European regulatory approval for CelGro which can now be sold in the European Union and is being readied for first approval in the the US and Australia. Other products include TGA-licensed cell therapies, Autologous Chondrocyte Implantation (Ortho-ACI) and Autologous Tenocyte Implantation (Ortho-ATI), which targets at the damaged cartilage tissue and tendon for the purpose of regeneration.

On 6th March 2019, the company released a statement that the clinical trial of Orthocell’s Autologous Tenocyte Injection (Ortho-ATI) versus corticosteroids injections is on track for recruitment completion by 2Q CY 2019. The study is targeted specifically for the treatment of rotator cuff tendinopathy and tear in the shoulder.

The trial is led by Clinical Professor Allan Wang (former President of the Australian Elbow and Shoulder Society), Dr Jeff Hughes (current President of the Australian Elbow and Shoulder Society), Dr Jane Fitzpatrick, Dr Travis Falconer and Professor Ming Hao Zheng at the University of Western Australia (UWA). The patients must have failed previous conservative treatment options, including previous injection treatment and physiotherapy in order to be eligible for the clinical trial.

The Rotator cuff tendinopathy and tear is so common that it affects more than 50% of adults over 50 years of age. It is an often-difficult injury to treat, and if untreated, it manifests as severe shoulder pain. Rotator cuff injuries put a lot of burden on healthcare resources which is expected to increase as the population ages. Therefore, new treatments are required to address the core of this disorder and not just the symptoms or temporary solutions.

Ortho-ATI is used to treat tendon injuries (tendinopathy / tendonitis). Tendinopathy puts a lot of financial burden on the public healthcare system which is expected to increase as the changes of occurrence of tendinopathy increases with age. This has increased the demand for the treating physicians and insurers who are constantly seeking improvements in the treatments to make it more safe, efficient and cost-effective. Orthocell’s Ortho-ATI helps to address this growing demand by directly addressing the core of the injury. Ortho-ATI has 4.5 years of clinical data of post-treatment in leading peer-reviewed journals like American Journal Sports Medicine which has proven its extensive clinical validation and demonstrating durability and efficacy as the leading tendon regeneration treatment

The company’s stock closed the day’s session at A$0.13 as of 6th March 2019. The stock has soared by 3.70% over last 5 days.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.